| Ms Michelle Rabinovich, DO | |
|
13515 Wolfe Rd Ste C, New Freedom, PA 17349-9346 | |
| (717) 812-2501 | |
| (717) 461-7178 |
| Full Name | Ms Michelle Rabinovich |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 11 Years |
| Location | 13515 Wolfe Rd Ste C, New Freedom, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962849505 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | OS018137 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| York Hospital | York, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wellspan Medical Group | 1951213115 | 1946 |
News Archive
Boston Scientific Corporation today announced its exclusive sponsorship and first enrollments of the MADIT-RIT clinical trial. This new trial follows in the tradition of three previous landmark trials: MADIT, MADIT II and MADIT-CRT, each exclusively sponsored by Boston Scientific and conducted under the leadership of Principal Investigator Arthur J. Moss, M.D., Professor of Medicine at the University of Rochester.
A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia, according to a study led in part by Dana-Farber Cancer Institute investigators.
Approximately 12,000 spinal cord injuries (SCI) happen every year in the U.S., the majority caused by car accidents, falls, sporting accidents and gunshot wounds.
New data from a Phase I clinical trial led by Clark Chen, M.D., Ph.D., Lyle French Chair in Neurosurgery and Head of the University of Minnesota Medical School Department of Neurosurgery shows more than a quarter of patients with recurrent high-grade glioma, a form of brain cancer, were alive more than three years after treatment.
› Verified 7 days ago
| Entity Name | Wellspan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750480299 PECOS PAC ID: 1951213115 Enrollment ID: O20040220000815 |
News Archive
Boston Scientific Corporation today announced its exclusive sponsorship and first enrollments of the MADIT-RIT clinical trial. This new trial follows in the tradition of three previous landmark trials: MADIT, MADIT II and MADIT-CRT, each exclusively sponsored by Boston Scientific and conducted under the leadership of Principal Investigator Arthur J. Moss, M.D., Professor of Medicine at the University of Rochester.
A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia, according to a study led in part by Dana-Farber Cancer Institute investigators.
Approximately 12,000 spinal cord injuries (SCI) happen every year in the U.S., the majority caused by car accidents, falls, sporting accidents and gunshot wounds.
New data from a Phase I clinical trial led by Clark Chen, M.D., Ph.D., Lyle French Chair in Neurosurgery and Head of the University of Minnesota Medical School Department of Neurosurgery shows more than a quarter of patients with recurrent high-grade glioma, a form of brain cancer, were alive more than three years after treatment.
› Verified 7 days ago
| Entity Name | Medexpress Urgent Care Pc - Pennsylvania |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982839031 PECOS PAC ID: 8224181482 Enrollment ID: O20090805000511 |
News Archive
Boston Scientific Corporation today announced its exclusive sponsorship and first enrollments of the MADIT-RIT clinical trial. This new trial follows in the tradition of three previous landmark trials: MADIT, MADIT II and MADIT-CRT, each exclusively sponsored by Boston Scientific and conducted under the leadership of Principal Investigator Arthur J. Moss, M.D., Professor of Medicine at the University of Rochester.
A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia, according to a study led in part by Dana-Farber Cancer Institute investigators.
Approximately 12,000 spinal cord injuries (SCI) happen every year in the U.S., the majority caused by car accidents, falls, sporting accidents and gunshot wounds.
New data from a Phase I clinical trial led by Clark Chen, M.D., Ph.D., Lyle French Chair in Neurosurgery and Head of the University of Minnesota Medical School Department of Neurosurgery shows more than a quarter of patients with recurrent high-grade glioma, a form of brain cancer, were alive more than three years after treatment.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Michelle Rabinovich, DO 3421 Concord Rd, York, PA 17402-9001 Ph: (717) 812-2501 | Ms Michelle Rabinovich, DO 13515 Wolfe Rd Ste C, New Freedom, PA 17349-9346 Ph: (717) 812-2501 |
News Archive
Boston Scientific Corporation today announced its exclusive sponsorship and first enrollments of the MADIT-RIT clinical trial. This new trial follows in the tradition of three previous landmark trials: MADIT, MADIT II and MADIT-CRT, each exclusively sponsored by Boston Scientific and conducted under the leadership of Principal Investigator Arthur J. Moss, M.D., Professor of Medicine at the University of Rochester.
A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia, according to a study led in part by Dana-Farber Cancer Institute investigators.
Approximately 12,000 spinal cord injuries (SCI) happen every year in the U.S., the majority caused by car accidents, falls, sporting accidents and gunshot wounds.
New data from a Phase I clinical trial led by Clark Chen, M.D., Ph.D., Lyle French Chair in Neurosurgery and Head of the University of Minnesota Medical School Department of Neurosurgery shows more than a quarter of patients with recurrent high-grade glioma, a form of brain cancer, were alive more than three years after treatment.
› Verified 7 days ago
Dr. Nicholas Adam Lumsden, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 13515 Wolfe Rd, Ste C, New Freedom, PA 17349 Phone: 717-812-2501 Fax: 717-461-7178 | |
Samuel Boateng, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 13515 Wolfe Rd Ste C, New Freedom, PA 17349 Phone: 717-812-2501 Fax: 717-461-7178 | |
Amara Zubair Burney, M.D Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 13515 Wolfe Rd, Suite C, New Freedom, PA 17349 Phone: 717-812-2501 Fax: 717-812-2510 | |
Dr. Brian J Taylor, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 13515 Wolfe Rd, Suite C, New Freedom, PA 17349 Phone: 717-812-2501 Fax: 717-416-7178 | |
Patricia Chen, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 13515 Wolfe Rd Ste C, New Freedom, PA 17349 Phone: 717-812-2501 | |
Dr. Michelle Lorraine Schlosser, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 13515 Wolfe Rd, Suite C, New Freedom, PA 17349 Phone: 717-812-2501 Fax: 717-461-7178 | |
Dr. Douglas H Prince, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 13515 Wolfe Rd, Suite C, New Freedom, PA 17349 Phone: 717-812-2501 Fax: 717-461-7178 |